Sivik Global Healthcare’s Acadia Pharmaceuticals ACAD Stock Holding History

Sivik Global Healthcare’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-40,000	Closed	-$1.44M	–	52
2019 Q3	$1.44M	Sell	40,000 -10,000	-20%	-$303K	0.73%	39
2019 Q2	$1.34M	Buy	+50,000	New	+$1.28M	0.32%	60
2018 Q3	–	Sell	-47,351	Closed	-$723K	–	63
2018 Q2	$723K	Buy	+47,351	New	+$844K	0.28%	60
2018 Q1	–	Sell	-65,000	Closed	-$1.96M	–	60
2017 Q4	$1.96M	Sell	65,000 -55,000	-46%	-$1.76M	0.73%	59
2017 Q3	$4.52M	Buy	120,000 +65,000	+118%	+$2.11M	1.54%	26
2017 Q2	$1.53M	Sell	55,000 -10,000	-15%	-$298K	0.56%	61
2017 Q1	$2.23M	Sell	65,000 -5,000	-7%	-$176K	1.04%	37
2016 Q4	$2.02M	Buy	70,000 +4,423	+7%	+$117K	0.96%	39
2016 Q3	$2.09M	Buy	65,577 +8,077	+14%	+$274K	1.05%	37
2016 Q2	$1.87M	Sell	57,500 -42,500	-43%	-$1.42M	0.93%	49
2016 Q1	$2.8M	Buy	100,000 +40,000	+67%	+$872K	1.24%	33
2015 Q4	$2.14M	Buy	60,000 +3,686	+7%	+$130K	1.02%	46
2015 Q3	$1.86M	Buy	56,314 +6,314	+13%	+$263K	0.9%	45
2015 Q2	$2.09M	Buy	50,000 +15,000	+43%	+$581K	0.73%	54
2015 Q1	$1.14M	Buy	+35,000	New	+$1.2M	0.39%	72

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sivik Global Healthcare's ACAD Position: Q4 2019 in Review

Sivik Global Healthcare sold out of Acadia Pharmaceuticals (ACAD) in Q4 2019, closing a stake of 40,000 shares — an estimated $1.44M sold.

Sivik Global Healthcare first reported a position in ACAD in Q1 2015 and held it in 15 quarters. The position peaked at $4.52M in Q3 2017. 273 funds tracked by Wall St. Rank hold ACAD as of Q4 2019.

Sivik Global Healthcare reported no remaining Acadia Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Sivik Global Healthcare sold 40,000 Acadia Pharmaceuticals shares in Q4 2019, an estimated $1.44M.
Sivik Global Healthcare first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 15 quarters.
Sivik Global Healthcare's Acadia Pharmaceuticals position peaked at $4.52M in Q3 2017.
273 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2019.

Based on Sivik Global Healthcare's 13F filing for Q4 2019, filed 13 Feb 2020.